Calliditas Therapeutics AB
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Calliditas Therapeutics AB sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Calliditas Therapeutics AB: 5 sponsored US clinical trials, 1 recruiting.
Calliditas Therapeutics AB sponsors 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 4 completed. 3 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Type 2 Diabetes Mellitus With Diabetic Nephropathy, with 1 trials.
Upper-quartile sponsor footprint
Calliditas Therapeutics AB sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
NCT06712407
Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)
NCT04541043
Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy
NCT03643965
Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol.
NCT03226067
Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
NCT02010242
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 2 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Calliditas Therapeutics AB pipeline
1 recruiting of 5 indexed (20% open); 4 completed (80%).
Phase mix: 3 late (III/IV) vs 2 early (I/II) (balanced across stages).
Top condition: Type 2 Diabetes Mellitus With Diabetic Nephropathy (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Calliditas Therapeutics AB: open-pipeline peers nationwide
Peers matched on 5 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
Calliditas Therapeutics AB sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 20% open enrollment (± trial volume)
- Align Technology · 20% recruiting · 5 trials
- AltruBio · 20% recruiting · 5 trials
- Alvernia University · 20% recruiting · 5 trials
- Amazentis · 20% recruiting · 5 trials
Related
What to do with this Calliditas Therapeutics AB page
5 registered trials is a research-attention snapshot, not an endorsement of Calliditas Therapeutics AB or any single study.
- 1 of Calliditas Therapeutics AB's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Type 2 Diabetes Mellitus With Diabetic Nephropathy is the condition Calliditas Therapeutics AB studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Type 2 Diabetes Mellitus With Diabetic Nephropathy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Calliditas Therapeutics AB pipeline card: 5 registered trials from official public datasets.Report a data error.